What's new? Log in Free sign up

ProPhase Labs (PRPH) News and press releases

Company Profile

News

From Benzinga Pro

A Look Into Healthcare Sector Value Stocks

12 Health Care Stocks Moving In Wednesday's After-Market Session

5 Value Stocks In The Healthcare Sector

ProPhase Labs's Return On Capital Employed Overview

ProPhase Labs Acquires Rights To Novel Esophageal Cancer Test For ~$4.5M

Biotech, M&A, General

ProPhase Labs, Inc. "ProPhase" (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it has entered into an asset purchase agreement to acquire

5 Value Stocks In The Healthcare Sector

HC Wainwright & Co. Maintains Buy on ProPhase Labs, Raises Price Target to $15

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and raises the price target from $14 to $15.

ProPhase Labs Q3 EPS $0.06 Misses $0.19 Estimate, Sales $24.20M Beat $21.42M Estimate

ProPhase Labs (NASDAQ:PRPH) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.19 by 68.42 percent. This is a 123.08 percent increase over losses of $(0.26) per share from

Earnings Scheduled For November 10, 2022

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.

ProPhase Labs Announces Collaboration With Dana-Farber Cancer Institute

ProPhase Labs, Inc. (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), and

Press releases

From Benzinga Pro

ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test

GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. "ProPhase" (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it has entered into an

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the

ProPhase Labs Announces Record Third Quarter 2022 Financial Results

Q3 2022 Net Revenues of $24.2 Million (a Q3 record); Up 155% Year-over-Year Q3 2022 Net Income of $1.0 Million versus a loss in Q3 2021 Q3 2022 adjusted EBITDA of $6.3 million (a Q3 record) versus a loss in

ProPhase Labs to Present at Investor Summit Group's Q4 Conference

GARDEN CITY, NY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in the Q4